Physician profile
Mark R Kapperman
NPI 1295728863
$26,912.26
in general payments reported to CMS, 2019-2025
28 companies · $838 in 2025
The $838 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,729 · 2020: $1,222 · 2021: $926 · 2022: $9,870 · 2023: $7,268 · 2024: $2,059 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,465 · Travel and Lodging: $2,862 · Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,465.00 |
| Travel and Lodging | $2,861.89 |
| Food and Beverage | $2,838.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $23,052.42 | 2019-2025 | Air Optix, Dailies, Dailies Aqua Comfort Plus |
| Coopervision INC. | $1,302.30 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $355.94 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $276.89 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $254.53 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $234.00 | 2019-2025 | Contact Lens |
| Novartis Pharmaceuticals Corporation | $190.80 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $161.63 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $128.84 | 2023-2025 | Acthar |
| Allergan, INC. | $125.57 | 2019-2022 | |
| Abbvie INC. | $108.36 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $84.70 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $82.34 | 2021 | |
| Biotissue Holdings INC. | $82.13 | 2023-2024 | |
| Optos, INC. | $70.41 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $59.98 | 2024 | Cirrus Hd-Oct |
| Shire North American Group INC | $53.90 | 2019 | |
| Horizon Therapeutics Plc | $42.17 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Dompe US, INC. | $36.54 | 2024 | Oxervate |
| Topcon Healthcare, INC. | $32.93 | 2020 | |
| Maculogix, INC. | $25.14 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.56 | 2021 | |
| Thea Pharma INC. | $24.33 | 2024 | Iyuzeh |
| Lkc Technologies, INC. | $16.44 | 2025 | |
| Alcon Research LLC | $16.43 | 2019 | |
| Sight Sciences, INC. | $16.00 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kapperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.